People with existing risk factors who contract COVID are more likely to be hospitalised and progress to a series reaction to the virus.
Monoclonal antibody treatments such as Sotrovimab and now others have been used to ease the symptoms and help people recover, and the good news is there are more anti-viral treatments as well in the pipeline.
There is a new variant of Omicron occurring, and whilst it may appear to be more infectious, it may turn out to be less virulent or severe.
Produced By: Roderick Chambers
Featured In Story: Professor William Rawlinson, Senior Medical Virologist and Director of Virology University of New South Wales
First aired on The Wire, Monday 14 March 2022